IDEC-C2B8 antibody data

IDPH (San Diego, Calif.) presented preliminary data from a Phase II trial combining IDEC-C2B8, an antibody which targets the CD20 antigen on mature B cells and B cell tumors, with CHOP combination chemotherapy.

The overall response rate in 16 evaluable patients was 100 percent, with duration of 5-18 months. Eleven achieved a complete response and five achieved a partial response. Four patients who, prior to treatment, had a marker called bcl-2 that is associated with multi-drug resistance, lost the marker by the end of therapy. ...